When Ryan Frazier was only three months old, his family received life-changing news: he had acute myeloid leukemia (AML). Despite multiple rounds of chemotherapy, the cancer came back and spread to his central nervous system. His…
When Len Gardner was admitted to the NIH Clinical Center in 1955, he joined a clinical study that would ultimately save his life. Diagnosed with a serious kidney condition, he received an experimental drug—now known as…
Each year, more than 209,000 people in the U.S. are diagnosed with lung cancer, making it one of the most common—and challenging—cancers today. These numbers highlight not only the need for better treatments but also the…
The Ax-4 mission — Axiom Space’s fourth commercial astronaut flight to the International Space Station launched on June 25th and we’re thrilled to announce that TrialX is once again playing a key role in advancing space health…
Recruiting participants for clinical trials remains a significant challenge for sponsors. They often face inefficiencies that cause delays or trial failures, with up to 86% of trials experiencing recruitment difficulties. These delays incur millions of dollars…
Ensuring a thoughtful selection of a diverse participant pool from the outset not only minimizes recruitment delays but also enhances the credibility of trial outcomes. This approach diminishes the necessity for subsequent postmarketing data collection to…
In the dynamic world of clinical research, the paradigm is shifting towards more sophisticated and patient-centric trial designs. This shift is driven by the need to streamline drug development processes, which are characterized by high costs…
